A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation | Zendy

Omer Jamy | Zendy; Racquel Innis-Shelton | Zendy; Susan Bal | Zendy; Donna Salzman | Zendy; Luciano J. Costa | Zendy; Antonio Di Stasi | Zendy; Lawrence S. Lamb | Zendy; Shin Mineishi | Zendy; Ayman Saad | Zendy

Open Access

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Author(s) -

Omer Jamy,

Racquel Innis-Shelton,

Susan Bal,

Donna Salzman,

Luciano J. Costa,

Antonio Di Stasi,

Lawrence S. Lamb,

Shin Mineishi,

Ayman Saad

Publication year - 2020

Publication title -

biology of blood and marrow transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.301

H-Index - 120

eISSN - 1523-6536

pISSN - 1083-8791

DOI - 10.1016/j.bbmt.2019.12.756

Subject(s) - medicine , busulfan , fludarabine , graft versus host disease , hematopoietic stem cell transplantation , transplantation , cyclophosphamide , surgery , gastroenterology , population , clinical endpoint , stem cell , clinical trial , chemotherapy , environmental health , biology , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research